Full Text View
Tabular View
No Study Results Posted
Related Studies
Prospective Study of HIV Infection in Hemophiliacs
This study has been completed.
First Received: May 25, 2000   Last Updated: June 23, 2005   History of Changes
Sponsored by: National Heart, Lung, and Blood Institute (NHLBI)
Information provided by: National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier: NCT00005309
  Purpose

To examine mechanisms of individual differences in the progression of HIV infection in hemophiliacs.


Condition
Acquired Immunodeficiency Syndrome
HIV Infections
Blood Disease
Hemophilia A
Hepatitis, Viral, Human
Blood Transfusion
Cytomegalovirus Infections

Genetics Home Reference related topics: hemophilia
MedlinePlus related topics: AIDS Blood Transfusion and Donation Cytomegalovirus Infections Hemophilia Hepatitis
U.S. FDA Resources
Study Type: Observational
Study Design: Natural History

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: July 1990
Estimated Study Completion Date: March 1995
Detailed Description:

BACKGROUND:

In the late 1980s, hemophiliacs were transfused with a variety of blood products, including large amounts of cryoprecipitate. In comparison to other cohorts, hemophiliacs are CMV(-), resulting in a comparison group for the study of this virus as a potential cofactor. In contrast, non A, non-B hepatitis is common in comparison to other cohorts, and preliminary data prior to 1990 suggested that this chronic disease predisposes to more rapid progression of HIV infection.

DESIGN NARRATIVE:

Disease-free survival rates were determined in HIV-infected hemophiliacs. The effects of co-factors such as intensive transfusion, concomitant cytomegalovirus or chronic NANB hepatitis infection were ascertained. Host-virus interaction was assessed through the use of plasma cultures, specific antibody titers, and markers of immune changes detected by flow cytometry and immune function assays. The immunology of asymptomatic stable infection was investigated. The safety of volunteer donor blood products was determined in seronegative patients exposed to over 50,000 donors yearly and the risk of sexual transmission of HIV to spouses of seropositive patients was monitored.

  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

No eligibility criteria

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00005309

Sponsors and Collaborators
Investigators
Investigator: George Gjerset Puget Sound Blood Center
  More Information

No publications provided

Study ID Numbers: 3012
Study First Received: May 25, 2000
Last Updated: June 23, 2005
ClinicalTrials.gov Identifier: NCT00005309     History of Changes
Health Authority: United States: Federal Government

Study placed in the following topic categories:
Liver Diseases
Sexually Transmitted Diseases, Viral
Hematologic Diseases
Blood Coagulation Disorders
Acquired Immunodeficiency Syndrome
Hemophilia A
Hepatitis, Viral, Human
Hemostatic Disorders
Cytomegalovirus
Immunologic Deficiency Syndromes
Herpesviridae Infections
Hepatitis
Virus Diseases
Digestive System Diseases
Hemorrhagic Disorders
Genetic Diseases, Inborn
HIV Infections
Sexually Transmitted Diseases
Cytomegalic Inclusion Disease
Cytomegalovirus Infections
DNA Virus Infections
Retroviridae Infections

Additional relevant MeSH terms:
Communicable Diseases
Liver Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Hemophilia A
Hepatitis, Viral, Human
Infection
Pathologic Processes
Hemorrhagic Disorders
Syndrome
Cytomegalovirus Infections
Retroviridae Infections
RNA Virus Infections
Disease
Immune System Diseases
Hematologic Diseases
Coagulation Protein Disorders
Blood Coagulation Disorders
Acquired Immunodeficiency Syndrome
Immunologic Deficiency Syndromes
Herpesviridae Infections
Hepatitis
Virus Diseases
Digestive System Diseases
Blood Coagulation Disorders, Inherited
Genetic Diseases, Inborn
HIV Infections
Sexually Transmitted Diseases
Lentivirus Infections
DNA Virus Infections

ClinicalTrials.gov processed this record on May 07, 2009